Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines
- PMID: 2007575
Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines
Abstract
Determinants of methotrexate (MTX) resistance in cell lines resistant to short, but not continuous, MTX exposure were investigated since such lines may have relevance to clinical resistance. CCRF-CEM R30dm (R30dm), cloned from CCRF-CEM R30/6 (a MTX-resistant subline of the CCRF-CEM human leukemia cell line), had growth characteristics similar to CCRF-CEM. R30dm was resistant to a 24-h exposure to levels as high as 300 microM MTX but was as sensitive as CCRF-CEM to continuous MTX exposure. MTX resistance of R30dm was stable for greater than 68 weeks in the absence of selective pressure. Initial velocities of MTX transport were comparable for R30dm and CCRF-CEM, as were dihydrofolate reductase specific activity and MTX binding. A 2-fold thymidylate synthase activity decrease for R30dm from that of CCRF-CEM was not a significant factor in R30dm MTX resistance. Decreased MTX poly(gamma-glutamate) synthesis resulted in lower levels of drug accumulation by R30dm. Decreased polyglutamylation was attributable to folylpolyglutamate synthetase (FPGS) activity in R30dm extracts which was 1, 2, and less than or equal to 10% of CCRF-CEM extracts with the substrates MTX, aminopterin, and naturally occurring folates, respectively. Comparison of cell lines with varying levels of resistance to short term MTX exposure indicated that the extent of MTX resistance was proportional to the reduction of FPGS activity. The evidence supported decreased FPGS activity as the mechanism of resistance to short MTX exposure in the cell lines investigated.
Similar articles
-
Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.Leukemia. 1993 Dec;7(12):1996-2003. Leukemia. 1993. PMID: 8255099
-
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.Clin Cancer Res. 1999 Sep;5(9):2548-58. Clin Cancer Res. 1999. PMID: 10499632
-
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.Biochem Pharmacol. 2002 Jan 15;63(2):105-15. doi: 10.1016/s0006-2952(01)00824-3. Biochem Pharmacol. 2002. PMID: 11841783
-
Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.Int J Cancer. 2003 Feb 20;103(5):587-99. doi: 10.1002/ijc.10829. Int J Cancer. 2003. PMID: 12494465
-
Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.Adv Exp Med Biol. 1999;457:543-50. doi: 10.1007/978-1-4615-4811-9_59. Adv Exp Med Biol. 1999. PMID: 10500832 Review.
Cited by
-
FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia.Sci Rep. 2020 Jul 21;10(1):12074. doi: 10.1038/s41598-020-69059-y. Sci Rep. 2020. PMID: 32694622 Free PMC article.
-
Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.Front Oncol. 2020 Sep 25;10:541479. doi: 10.3389/fonc.2020.541479. eCollection 2020. Front Oncol. 2020. PMID: 33102213 Free PMC article.
-
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.Invest New Drugs. 2004 Nov;22(4):437-48. doi: 10.1023/B:DRUG.0000036686.86700.a9. Invest New Drugs. 2004. PMID: 15292714 Clinical Trial.
-
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.Br J Cancer. 1995 May;71(5):914-24. doi: 10.1038/bjc.1995.178. Br J Cancer. 1995. PMID: 7537518 Free PMC article.
-
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.BMC Cancer. 2021 Jul 31;21(1):879. doi: 10.1186/s12885-021-08607-9. BMC Cancer. 2021. PMID: 34332580 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials